Skip To Main Content
J. Yin on Muck Rack

J. Yin

As seen in: Color Research & Application, Wiley Online Library, Medscape, Science Magazine, BJA (British Journal of Anaesthesia)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with J.

Contact J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Correction to “Anisotropic Superconducting Nb2CTx MXene Processed by Atomic Exchange at the Wafer Scale”

|
By X. -Z. Xu, C. -Q. Zhang, J. Yin, J. Smajic
| Wiley Online Library Verified
Anisotropic Superconducting Nb2CTx MXene Processed by Atomic Exchange at the Wafer Scale. Adv. Mater. 2024, 36, 2305326. In the author list, the name “Chenghui Zhang” was misspelled. It is hereby corrected to “Chenhui Zhang”. We apologize for this error.
Open in Who Shared Issue with article?

Composite super-moiré lattices in double-aligned graphene heterostructures

|
By Zihao Wang, J. Yin, Oxford Road, Y. H. Yang
| Science Magazine Verified
Abstract When two-dimensional (2D) atomic crystals are brought into close proximity to form a van der Waals heterostructure, neighbouring crystals may influence each other’s properties. Of particular interest is when the two crystals closely match and a moiré pattern forms, resulting in modified electronic and excitonic spectra, crystal reconstruction, and more. Thus, moiré patterns are a viable tool for controlling the properties of 2D materials.
Open in Who Shared Issue with article?

Application of SMART Trial Design in Older Patients With CLL

|
By J. Yin, A. S. Ruppert, M. Davidian, A. A. Tsiatis
| Medscape Verified
Abstract and Introduction Abstract Background: Ibrutinib therapy is safe and effective in patients with chronic lymphocytic leukemia (CLL). Currently, ibrutinib is administered continuously until disease progression. Combination regimens with ibrutinib are being developed to deepen response which could allow for ibrutinib maintenance (IM) discontinuation.
Open in Who Shared Issue with article?
See all 7 articles